[{"from": "human", "value": "What can you tell me about this molecule? [C][C][Branch1][C][C][Branch2][Branch1][#Branch2][C][C][=Branch1][C][=O][N][C][C][N][C][=C][C][=C][Ring1][Branch1][C][=Branch1][=Branch1][=N][C][=N][Ring1][=Branch1][N][C][=C][C][=Branch2][Ring1][O][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][O][C][=C][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][C][Branch1][C][F][Branch1][C][F][F][Cl][O]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable, small molecule and dual kinase inhibitor of human epidermal growth factor receptors 1 (EGFR/ErbB1) and 2 (HER2/ErbB2), with potential antineoplastic activity. EGFR/HER2 kinase inhibitor TAK-285 binds to and inhibits EGFR and HER2, which may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumors. This agent may be active against EGFR/HER2-expressing tumor cells that are resistant to trastuzumab. EGFR and HER2, receptor tyrosine kinases overexpressed in a variety of tumor cell types, play major roles in tumor cell proliferation and tumor vascularization. In addition, TAK-285 appears to pass the blood brain barrier (BBB) and does not appear to be a substrate for efflux pumps."}]